Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Journal Club: A well-accepted and safe method for soft tissue sarcoma biopsy.

2.

Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.

3.

FDA approves Blenrep for relapsed or refractory multiple myeloma

4.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

5.

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot